Digest Network Come funziona
Network
/
Società
Bi
Non verificato

Biogen Inc.

Di cosa scriviamo

Annunci EconomiciBiotecnologiaFinanzaManagement/Organizzazione AziendaleMedicina Salute Benessere

51 comunicati stampa

Guarda tutti i comunicati
05/12/2025
Biotecnologia
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
24/11/2025
Biotecnologia
Medicina Salute Benessere
Management/Organizzazione Aziendale
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
17/11/2025
Biotecnologia
Medicina Salute Benessere
Annunci Economici
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
17/11/2025
Biotecnologia
Medicina Salute Benessere
Annunci Economici
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
14/11/2025
Biotecnologia
Medicina Salute Benessere
Annunci Economici
Biogen Completes Acquisition of Alcyone Therapeutics
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
03/11/2025
Biotecnologia
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
24/10/2025
Biotecnologia
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
22/10/2025
Biotecnologia
Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
13/10/2025
Biotecnologia
Annunci Economici
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0
09/10/2025
Biotecnologia
Medicina Salute Benessere
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
Fonte
Biogen Inc.
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0